BrightSpring Health Services, Inc. (BTSG)
| Market Cap | 13.30B +175.9% |
| Revenue (ttm) | 13.65B +28.0% |
| Net Income | 309.89M +441.5% |
| EPS | 1.40 +386.0% |
| Shares Out | 208.32M |
| PE Ratio | 45.64 |
| Forward PE | 36.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 282,829 |
| Open | 64.29 |
| Previous Close | 64.08 |
| Day's Range | 63.52 - 64.68 |
| 52-Week Range | 19.01 - 64.60 |
| Beta | 1.87 |
| Analysts | Strong Buy |
| Price Target | 62.56 (-2.01%) |
| Earnings Date | Jul 31, 2026 |
About BTSG
BrightSpring Health Services, Inc. operates as a home and community-based healthcare services platform in the United States. The company operates through two segments, Pharmacy Solutions and Provider Services. Its platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It also offers infused, injectable, and oral medication services; and patient-centric, highly skilled, and compassionate clinical home health care, as well... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for BTSG stock is "Strong Buy." The 12-month stock price target is $62.56, which is a decrease of -2.01% from the latest price.
News
BrightSpring Health Services, Inc. Welcomes Dr. Nigam H. Shah to Board of Directors
LOUISVILLE, Ky., June 12, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “the Company”) (NASDAQ: BTSG), a leading provider of home- and community-based pharmacy and health se...
FTC finalizes order requiring Sevita to divest 128 facilities
The Federal Trade Commission said it has finalized a consent order involving Sevita Health’s acquisition of BrightSpring Health’s (BTSG) community living business. The consent order requires Sevita to...
BrightSpring Health Services Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Achieved strong growth above historical targets, driven by specialty pharmacy, LDD wins, and operational efficiencies. Forward strategy focuses on integrated care, expansion in infusion and provider services, and disciplined M&A, with ongoing advocacy to address regulatory headwinds.
BrightSpring Health initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of BrightSpring Health (BTSG) with a Buy rating and $71 price target The firm says BrightSpring is showing accelerating business momentum. The company’s home- and comm...
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
LOUISVILLE, Ky., June 03, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services f...
BrightSpring announces offering of 15M shares of common stock for holders
BrightSpring Health (BTSG) Services announced that certain of its stockholders, including an affiliate of Kohlberg Kravis Roberts & Co. L.P. and certain members of management, intend to offer for sale...
BrightSpring Announces Secondary Offering of Common Stock and Concurrent Share Repurchase
LOUISVILLE, Ky., June 03, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services f...
BrightSpring Health Services Transcript: 46th Annual William Blair Growth Stock Conference
The company outlined its evolution into a dual pharmacy and provider platform focused on home and community health, leveraging scale, technology, and M&A for growth. With strong financial performance, ongoing innovation in AI, and plans to expand value-based care, it is positioned for continued market share gains.
BrightSpring Health price target raised to $71 from $62 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BrightSpring Health (BTSG) to $71 from $62 and keeps an Overweight rating on the shares. After having hosted BrightSpring’s CEO and CFO…
BrightSpring Health price target raised to $70 from $60 at BMO Capital
BMO Capital raised the firm’s price target on BrightSpring Health (BTSG) to $70 from $60 and keeps an Outperform rating on the shares. The firm has leveraged AI to map…
BrightSpring Health price target raised to $66 from $63 at BofA
BofA analyst Joanna Gajuk raised the firm’s price target on BrightSpring Health (BTSG) to $66 from $63 and keeps a Buy rating on the shares. The tone of CFO Jennifer…
BrightSpring Health price target raised to $62 from $48 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BrightSpring Health (BTSG) to $62 from $48 and keeps an Overweight rating on the shares.
BrightSpring Health price target raised to $61 from $52 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on BrightSpring Health (BTSG) to $61 from $52 and keeps an Outperform rating on the shares.
BrightSpring Health price target raised to $60 from $50 at Deutsche Bank
Deutsche Bank raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $50 and keeps a Buy rating on the shares.
BrightSpring Health price target raised to $60 from $52 at BMO Capital
BMO Capital raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $52 and keeps an Outperform rating on the shares. The magnitude of the company’s Q1 earnings…
BrightSpring Health price target raised to $65 from $60 at TD Cowen
TD Cowen raised the firm’s price target on BrightSpring Health (BTSG) to $65 from $60 and keeps a Buy rating on the shares. The firm updated its model following Q1…
BrightSpring Health price target raised to $64 from $53 at Stephens
Stephens raised the firm’s price target on BrightSpring Health (BTSG) to $64 from $53 and keeps an Overweight rating on the shares. BrightSpring’s 7% revenue and 12% EBITDA beat was…
BrightSpring Health price target raised to $65 from $55 at BTIG
BTIG raised the firm’s price target on BrightSpring Health (BTSG) to $65 from $55 and keeps a Buy rating on the shares after its Q1 earnings beat. While some investors…
BrightSpring Health price target raised to $61 from $50 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on BrightSpring Health (BTSG) to $61 from $50 and keeps an Overweight rating on the shares following very strong Q1…
BrightSpring Health price target raised to $60 from $55 at KeyBanc
KeyBanc raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $55 and keeps an Overweight rating on the shares. The firm says results were once again impressive,…
BrightSpring Health price target raised to $60 from $52 at BMO Capital
BMO Capital raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $52 and keeps an Outperform rating on the shares.
BrightSpring Health Services Earnings Call Transcript: Q1 2026
Q1 2026 saw 26% revenue growth and 45% adjusted EBITDA growth, driven by strong specialty and infusion performance, operational efficiencies, and successful integration of acquisitions. Guidance for 2026 was raised, with continued focus on margin expansion and disciplined capital allocation.
BrightSpring Health Services Slides: Q1 2026
BrightSpring Health Services has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 1, 2026.
BrightSpring Health Services Earnings release: Q1 2026
BrightSpring Health Services released its Q1 2026 earnings on May 1, 2026, summarizing the period's financial results.
BrightSpring Health Services Quarterly report: Q1 2026
BrightSpring Health Services has published its Q1 2026 quarterly earnings report on May 1, 2026.